Drug interactions between Cymbalta and iron polysaccharide
Interactions between your drugs
There were no interactions found in our database between Cymbalta and iron polysaccharide - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Cymbalta is in the drug class serotonin-norepinephrine reuptake inhibitors.
- Cymbalta is used to treat the following conditions:
- Iron polysaccharide is a member of the drug class iron products.
- Iron polysaccharide is used to treat Iron Deficiency Anemia.
Drug and food interactions
Applies to: Cymbalta (duloxetine)
DULoxetine may cause liver damage, and taking it with alcohol may increase that risk. You should avoid or limit the use of alcohol while being treated with DULoxetine. Call your doctor immediately if you have fever, chills, joint pain or swelling, excessive tiredness or weakness, unusual bleeding or bruising, skin rash or itching, loss of appetite, nausea, vomiting, dark colored urine, or yellowing of the skin or the whites of your eyes, as these may be symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
iron polysaccharide food
Applies to: iron polysaccharide
Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
For clinical details see professional interaction data.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|